Literature DB >> 11036040

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.

V Joly1, M Moroni, E Concia, A Lazzarin, B Hirschel, J Jost, F Chiodo, Z Bentwich, W C Love, D A Hawkins, E G Wilkins, A J Gatell, N Vetter, C Greenwald, W W Freimuth, W de Cian.   

Abstract

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11036040      PMCID： PMC101620          DOI： 10.1128/AAC.44.11.3155-3157.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

Authors:  L M Demeter; R W Shafer; P M Meehan; J Holden-Wiltse; M A Fischl; W W Freimuth; M F Para; R C Reichman
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.

Authors:  P Gerondelis; R H Archer; C Palaniappan; R C Reichman; P J Fay; R A Bambara; L M Demeter
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.

Authors:  A Carr; S Vella; M D de Jong; F Sorice; A Imrie; C A Boucher; D A Cooper
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

4.  ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.

Authors:  M F Para; P Meehan; J Holden-Wiltse; M Fischl; G Morse; R Shafer; L M Demeter; K Wood; T Nevin; N Virani-Ketter; W W Freimuth
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.

Authors: 
Journal:  Lancet       Date:  1996-08-03       Impact factor: 79.321

6.  Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

Authors:  R T Davey; D G Chaitt; G F Reed; W W Freimuth; B R Herpin; J A Metcalf; P S Eastman; J Falloon; J A Kovacs; M A Polis; R E Walker; H Masur; J Boyle; S Coleman; S R Cox; L Wathen; C L Daenzer; H C Lane
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

7.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

8.  Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

Authors:  R T D'Aquila; M D Hughes; V A Johnson; M A Fischl; J P Sommadossi; S H Liou; J Timpone; M Myers; N Basgoz; M Niu; M S Hirsch
Journal:  Ann Intern Med       Date:  1996-06-15       Impact factor: 25.391
  8 in total
  5 in total

1.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

Review 2.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

3.  Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.

Authors:  Véronique Joly; Diane Descamps; Gilles Peytavin; Fatiha Touati; France Mentre; Xavier Duval; Séverine Delarue; Patrick Yeni; Françoise Brun-Vezinet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

4.  The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.

Authors:  Yuncong Wang; Hui Xing; Lingjie Liao; Zhe Wang; Bin Su; Quanbi Zhao; Yi Feng; Pengfei Ma; Jia Liu; Jianjun Wu; Yuhua Ruan; Yiming Shao
Journal:  AIDS Res Ther       Date:  2014-11-21       Impact factor: 2.250

5.  HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients.

Authors:  Hui Xing; Yuhua Ruan; Jingyun Li; Hong Shang; Ping Zhong; Xia Wang; Lingjie Liao; Hanping Li; Min Zhang; Yile Xue; Zhe Wang; Bin Su; Wei Liu; Yonghui Dong; Yanling Ma; Huiqin Li; Guangming Qin; Lin Chen; Xiaohong Pan; Xi Chen; Guoping Peng; Jihua Fu; Ray Y Chen; Laiyi Kang; Yiming Shao
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.